Transition from parenteral treprostinil to selexipag aiming at hemodynamic targets in pulmonary arterial hypertension.

ABSTRACT:

Background

This study aimed to evaluate the progress of treatment with intensive targeted therapy in high-risk pulmonary arterial hypertension (PAH) patients and focused on setting an appropriate hemodynamic target of pulmonary vascular resistance (PVR) ≤4 Wood units (WU) and mean pulmonary arterial pressure (mPAP) ≤ 40 mmHg.

Methods

We retrospectively evaluated high-risk PAH patients who were administered treprostinil at a single tertiary pulmonary hypertension center between January 2020 and December 2022. Echocardiography, right heart catheterization, 6-minute walk distance (6MWD), and blood tests were obtained 6 and 12 months after the initiation of parenteral treprostinil administration.

Results

Twelve patients (1 male and 11 female; median age, 47.0 years [inter

SUBMITTER: Won Y 

PROVIDER: S-EPMC11800282 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature